BRCA1 and breast cancer: The estimated QALY/LYG for RRS were quite heterogenous across the studies above, mainly due to the variation in the assumptions related to age of RRS, BC-risk reduction from RRSO, hormone replacement therapy (HRT) uptake after RRSO, disutility from RRS and separate/combined analysis for BRCA1/2 PV carriers.